<SEC-DOCUMENT>0001520138-22-000313.txt : 20220718
<SEC-HEADER>0001520138-22-000313.hdr.sgml : 20220718
<ACCEPTANCE-DATETIME>20220718171030
ACCESSION NUMBER:		0001520138-22-000313
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220715
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220718
DATE AS OF CHANGE:		20220718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		221089807

	BUSINESS ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703
		BUSINESS PHONE:		775-888-3162

	MAIL ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>bivi-20220715_8ka1.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:bivi="http://nanoantibiotics.com/20220715">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_bivi_nanoantibiotics.com_20220715 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220715_20220715 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001580149 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityCentralIndexKey">0001580149</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:AmendmentFlag">true</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bivi-20220715.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-15to2022-07-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-15</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 3pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></span><b><br />
WASHINGTON, D.C. 20549</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 45%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20220715__20220715_zfGGrm0PI0N4"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:DocumentType">8-K/A</ix:nonNumeric></span><br />
<span style="font-size: 10pt">(Amendment No. 1)</span></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 45%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding-bottom: 0.75pt">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CURRENT REPORT PURSUANT<br />
TO SECTION 13 OR 15(d) OF<br />
THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported) <b><span id="xdx_905_edei--DocumentPeriodEndDate_c20220715__20220715_z7XRUt1uKD97"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July
15, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20220715__20220715_znsS7LeCINj"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityRegistrantName">BioVie Inc.</ix:nonNumeric></span></span></b></span><b><span style="text-decoration: underline"><br />
</span></b>(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 34%; text-align: center"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220715__20220715_zBnFzLtReM8d"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><b><span id="xdx_903_edei--EntityFileNumber_c20220715__20220715_zmKrT8dVSb9a"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityFileNumber">001-39015</ix:nonNumeric></span></b></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 34%; text-align: center"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20220715__20220715_zLZ5W9bn7fK5"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityTaxIdentificationNumber">46-2510769</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center">(State or Other Jurisdiction<br />
of Incorporation)</td>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: top; text-align: center">(I.R.S. Employer Identification No.)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 34%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20220715__20220715_zkWjFODgUdwd"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressAddressLine1">680 W Nye Lane Suite 201</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20220715__20220715_zWPyzEYQ8QYi"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressCityOrTown">Carson City</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220715__20220715_z8u5wvKaZv1d"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric></span></b></p></td>
    <td style="border-bottom: black 1.5pt solid; width: 32%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220715__20220715_znQkBQ051fIa"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:EntityAddressPostalZipCode">89703</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of Principal Executive Offices)</td>
    <td>&#160;</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(<span id="xdx_902_edei--CityAreaCode_c20220715__20220715" title="City Area Code"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:CityAreaCode">775</ix:nonNumeric></span>) <span id="xdx_90C_edei--LocalPhoneNumber_c20220715__20220715" title="Local Phone Number"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:LocalPhoneNumber">888-3162</ix:nonNumeric></span> <span style="text-decoration: underline"><br />
</span></b>(Registrant&#8217;s Telephone Number, Including Area Code)</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-top: black 1.5pt solid; width: 100%; padding-bottom: 0.5pt; text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former Name or Former Address, if Changed Since Last
Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1.5pt solid; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Title of each class</td>
    <td style="border-top: black 1.5pt solid; width: 20%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Trading Symbol(s)</td>
    <td style="border-top: black 1.5pt solid; width: 40%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Name of each exchange on which<br />
registered</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_902_edei--Security12bTitle_c20220715__20220715_zf1u8Da2IaK4"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:Security12bTitle">Class A Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_904_edei--TradingSymbol_c20220715__20220715_z3TybFwms5Yj"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:TradingSymbol">BIVI</ix:nonNumeric></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_900_edei--SecurityExchangeName_c20220715__20220715_z3v50iQAvEw9"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_908_edei--WrittenCommunications_c20220715__20220715_zlWWATb3uAe6"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_904_edei--SolicitingMaterial_c20220715__20220715_zfh1JM2Zah26"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_903_edei--PreCommencementTenderOffer_c20220715__20220715_zDQM2hGokO88"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20220715__20220715_z3ez0cnqdcRc"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in">Indicate by check mark whether the registrant is an
emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in">Emerging growth company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20220715__20220715_zCbusownNA6h"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 3pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->
<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory Note</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--AmendmentDescription_c20220715__20220715_z1kOdFvcvGZe"><ix:nonNumeric contextRef="From2022-07-15to2022-07-15" name="dei:AmendmentDescription">BioVie
Inc., a Nevada corporation (the &#8220;Company&#8221;), is filing this Amendment No. 1 on Form 8-K/A (this &#8220;Amendment&#8221;) to
amend the Current Report on Form 8-K, originally filed by the Company with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on July 15, 2022 (the &#8220;Original Report&#8221;), solely to delete references to the placement agent that were inadvertently included
in the Original Report and Exhibit 10.1 due to an administrative error. The full text of the Original Report is repeated in this Amendment
for convenience, but has not been modified from the text of the Original Report except as described above.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 5pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 5pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><b>Item 1.01</b></td>
    <td style="width: 90%; text-align: justify"><b>Entry into a Material Definitive Agreement.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0in"><b><i>Securities Purchase Agreement</i></b></p>

<p style="margin: 10pt 0in 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2022, BioVie
Inc., a Nevada corporation (the &#8220;Company&#8221;), entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;)
with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;), the Company&#8217;s controlling stockholder that is 100% owned by Terren
Peizer, the chairman of the Company&#8217;s board of directors, pursuant to which the Company agreed to issue and sell to Acuitas,
and Acuitas agreed to purchase from the Company, in a private placement (the &#8220;Private Placement&#8221;), (i) an aggregate
of 3,636,364 shares (the &#8220;PIPE Shares&#8221;) of the Company&#8217;s Class A common stock, par value $0.0001 per share (the
&#8220;Common Stock&#8221;), at a price of $1.65 per share, and (ii) a warrant (the &#8220;Warrant&#8221;) to purchase 7,272,728
shares of Common Stock (the &#8220;Warrant Shares&#8221;) at an exercise price of $1.82, with a term of exercise of five years.
The aggregate purchase price for the PIPE Shares and Warrant (collectively, the &#8220;Securities&#8221;) sold in the Private
Placement was approximately $6 million.</span></p>



<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">The Company expects the Private Placement to close on or
about August 15, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from
the Private Placement for working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">The Purchase Agreement includes representations,
warranties, and covenants customary for a transaction of this type. In addition, the Company agreed to indemnify Acuitas from liabilities
relating to the Company&#8217;s breach of any of the representations, warranties and covenants in the Purchase Agreement. The Securities
were sold pursuant to the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
and Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">Upon the closing of the Purchase Agreement,
the Company and Acuitas will amend and restate that certain Registration Rights Agreement, dated as of June 10, 2021, by and between the
Company and Acuitas (the &#8220;Existing Registration Rights Agreement&#8221;), to amend the definition of &#8220;Registrable Securities&#8221;
in the Existing Registration Rights Agreement to include the PIPE Shares and the Warrant Shares as Registrable Securities thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing description of the Purchase Agreement
and Warrant is not complete and is subject to and qualified in its entirety by reference to the full text of the Purchase Agreement and
the Form of Warrant, respectively, copies of which are attached as Exhibits 10.1 and 4.1 to this Current Report on Form 8-K, respectively,
and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 10%; text-align: justify"><b>Item 3.02</b></td>
    <td style="padding: 0.25pt; text-align: justify; width: 90%"><b>Unregistered Sales of Equity Securities. </b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0in; text-align: justify">The information provided in Item
1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02.</p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><b>Item 9.01</b></td>
    <td style="text-align: justify; width: 90%"><b><span style="text-decoration: underline">Financial Statements and Exhibits</span></b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 10%"><b>Exhibit No.</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 88%"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="bivi-20220715_8ka1ex4z1.htm">4.1</a></td>
    <td>&#160;</td>
    <td><a href="bivi-20220715_8ka1ex4z1.htm">Form of Common Stock Purchase Warrant.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="bivi-20220715_8ka1ex10z1.htm">10.1</a></td>
    <td>&#160;</td>
    <td><a href="bivi-20220715_8ka1ex10z1.htm">Securities Purchase Agreement, dated July 15, 2022, by and between the Company and Acuitas Group Holdings, LLC.</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 5pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 5pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: July 18, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td colspan="2"><b>BIOVIE INC.</b></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="width: 52%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 38%">&#160;</td>
    <td style="width: 5%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>By:</td>
    <td style="border-bottom: black 1.5pt solid">/s/ Joanne Wendy Kim</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">Name:</td>
    <td style="vertical-align: top">Joanne Wendy Kim</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">Title:</td>
    <td style="vertical-align: top">Chief Financial Officer</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 5pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div>
    <!-- Field: /Page -->

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lpoURembFi1iFSkivga7SrDNlk38O5K3NLaIy8KyzHwzQgxETktTI8NxXhawx6attUco8YyM9oTBka3WKYRb4sU4z9r67v2BGQUGAzOO1UgHobPejcMqBTkZqukwSUDJVE5hthHRV8/Ink2F1htdg7YV7JhaNug1v/qEvX6SpebVVR2QnSGbgoplL78hkSqBLd31g/jqoCgyEQ26iUTOdGu/NTfnqYFFjU3ocj363+gDEoJJPw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>bivi-20220715_8ka1ex4z1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">NEITHER THIS SECURITY
NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SERIES 2022-I COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 49%">Warrant Shares: 7,272,728</TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="text-align: right; width: 49%">Issue Date: ____, 2022</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">THIS SERIES 2022-I COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, Acuitas Group Holdings, LLC or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
______, 2022 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on _______ (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from BioVie Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
up to 7,272,728 shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated July 15, 2022, among the Company and the
purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy
submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of
Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the
aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Business Days of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)
Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">b)&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $1.82, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a
number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left">(A)&nbsp;=</TD><TD STYLE="text-align: justify"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on
a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day
immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal
Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of
the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading
Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to
Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left">(B)&nbsp;=</TD><TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left">(X)&nbsp;=</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable
upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.
The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported
on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate
or book-entry statement, as specified by the Holder, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the
Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)
the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise
(such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be
deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant
has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain
a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used
herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading
Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the
Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">b) <U>Subsequent
Equity Sales</U>. If the Company, at any time while this Warrant is outstanding, shall issue shares of Common Stock or securities
or rights convertible or exchangeable into shares of Common Stock (&ldquo;<U>Common Stock Equivalents</U>&rdquo;) entitling any
person to acquire shares of Common Stock, at a price per share less than the then current Exercise Price (such issuances, collectively,
a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any
time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or
otherwise, or due to warrants, options or rights issued in connection with such issuance, be entitled to receive shares of Common
Stock at a price less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price),
then, the Exercise Price shall be reduced to such lower price per share. Such adjustment shall be made whenever such Common Stock
or Common Stock Equivalents are issued. The Company shall notify the Holder in writing, no later than the third trading day following
the issuance of any Common Stock or Common Stock Equivalent subject to this Section 3(b), indicating therein the applicable issuance
price, or applicable reset price, exchange price, conversion price and other pricing terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">For purposes
of this Section 3(b), the following subsections (i) to (v) shall also be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 1in">(i) <U>Issuance
of Rights or Options</U>. In case at any time the Company shall in any manner grant (directly and not by assumption in a merger
or otherwise) any warrants or other rights to subscribe for or to purchase, or any options for the purchase of, Common Stock or
any stock or security convertible into or exchangeable for Common Stock (such warrants, rights or options being called &ldquo;Options&rdquo;
and such convertible or exchangeable stock or securities being called &ldquo;<U>Convertible Securities</U>&rdquo;) whether or not
such Options or the right to convert or exchange any such Convertible Securities are immediately exercisable, and the price per
share for which Common Stock is issuable upon the exercise of such Options or upon the conversion or exchange of such Convertible
Securities (determined by dividing (i) the sum (which sum shall constitute the applicable consideration) of (x) the total amount,
if any, received or receivable by the Company as consideration for the granting of such Options, plus (y) the aggregate amount
of additional consideration payable to the Company upon the exercise of all such Options, plus (z), in the case of such Options
which relate to Convertible Securities, the aggregate amount of additional consideration, if any, payable upon the issue or sale
of such Convertible Securities and upon the conversion or exchange thereof, by (ii) the total maximum number of shares of Common
Stock issuable upon the exercise of such Options or upon the conversion or exchange of all such Convertible Securities issuable
upon the exercise of such Options) shall be less than the Exercise Price in effect immediately prior to the time of the granting
of such Options, then the total number of shares of Common Stock issuable upon the exercise of such Options or upon conversion
or exchange of the total amount of such Convertible Securities issuable upon the exercise of such Options shall be deemed to have
been issued for such price per share as of the date of granting of such Options or the issuance of such Convertible Securities
and thereafter shall be deemed to be outstanding for purposes of adjusting the Exercise Price. Except as otherwise provided below,
no adjustment of the Exercise Price shall be made upon the actual issue of such Common Stock or of such Convertible Securities
upon exercise of such Options or upon the actual issue of such Common Stock upon conversion or exchange of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 1in">(ii) <U>Issuance
of Convertible Securities</U>. In case the Company shall in any manner issue (directly and not by assumption in a merger or otherwise)
or sell any Convertible Securities, whether or not the rights to exchange or convert any such Convertible Securities are immediately
exercisable, and the price per share for which Common Stock is issuable upon such conversion or exchange (determined by dividing
(i) the sum (which sum shall constitute the applicable consideration) of (x) the total amount received or receivable by the Company
as consideration for the issue or sale of such Convertible Securities, plus (y) the aggregate amount of additional consideration,
if any, payable to the Company upon the conversion or exchange thereof, by (ii) the total number of shares of Common Stock issuable
upon the conversion or exchange of all such Convertible Securities) shall be less than the Exercise Price in effect immediately
prior to the time of such issue or sale, then the total maximum number of shares of Common Stock issuable upon conversion or exchange
of all such Convertible Securities shall be deemed to have been issued for such price per share as of the date of the issue or
sale of such Convertible Securities and thereafter shall be deemed to be outstanding for purposes of adjusting the Exercise Price,
provided that (a) except as otherwise provided in subsection (iii) below, no adjustment of the Exercise Price shall be made upon
the actual issuance of such Common Stock upon conversion or exchange of such Convertible Securities and (b) no further adjustment
of the Exercise Price shall be made by reason of the issue or sale of Convertible Securities upon exercise of any Options to purchase
any such Convertible Securities for which adjustments of the Exercise Price have been made pursuant to the other provisions of
this Section 3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 1in">(iii) <U>Change
in Option Price or Conversion Rate</U>. Upon the happening of any of the following events, namely, if the purchase price provided
for in any Option referred to above, the additional consideration, if any, payable upon the conversion or exchange of any Convertible
Securities referred to above, or the rate at which Convertible Securities referred to above are convertible into or exchangeable
for Common Stock shall change at any time (including, but not limited to, changes under or by reason of provisions designed to
protect against dilution), the Exercise Price in effect at the time of such event shall forthwith be readjusted to the Exercise
Price which would have been in effect at such time had such Options or Convertible Securities still outstanding provided for such
changed purchase price, additional consideration or conversion rate, as the case may be, at the time initially granted, issued
or sold. On the termination of any Option for which any adjustment was made pursuant to this Section 3(b) or any right to convert
or exchange Convertible Securities for which any adjustment was made pursuant to this Section 3(b) (including without limitation
upon the redemption or purchase for consideration of such Convertible Securities by the Company), the Exercise Price then in effect
hereunder shall forthwith be changed to the Exercise Price which would have been in effect at the time of such termination had
such Option or Convertible Securities, to the extent outstanding immediately prior to such termination, never been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 1in">(iv) <U>Consideration
for Stock</U>. In case any shares of Common Stock, Options or Convertible Securities shall be issued or sold for cash, the consideration
received therefor shall be deemed to be the gross amount received by the Company therefor, before any deduction therefrom of any
expenses incurred or any underwriting commissions or concessions paid or allowed by the Company in connection therewith. In case
any shares of Common Stock, Options or Convertible Securities shall be issued or sold for a consideration other than cash, the
amount of the consideration other than cash received by the Company shall be deemed to be the fair value of such consideration
as determined in good faith by the board of directors of the Company (the &ldquo;<U>Board</U>&rdquo;), after deduction of any expenses
incurred or any underwriting commissions or concessions paid or allowed by the Company in connection therewith. In case any Options
shall be issued in connection with the issue and sale of other securities of the Company, together comprising one integral transaction
in which no specific consideration is allocated to such Options by the parties thereto, such Options shall be deemed to have been
issued for such consideration as determined in good faith by the Board. If Common Stock, Options or Convertible Securities shall
be issued or sold by the Company and, in connection therewith, other Options or Convertible Securities (the &ldquo;<U>Additional
Rights</U>&rdquo;) are issued, then the consideration received or deemed to be received by the Company shall be reduced by the
fair market value of the Additional Rights (as determined using a method mutually agreed to by the Company and the Holder). The
Board shall respond promptly, in writing, to an inquiry by the Holder as to the fair market value of the Additional Rights. In
the event that the Board and the Holder are unable to agree upon the fair market value of the Additional Rights, the Company and
the Holder shall jointly select an appraiser, who is experienced in such matters. The decision of such appraiser shall be final
and conclusive, and the cost of such appraiser shall be borne evenly by the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 1in">(v) <U>Record
Date</U>. In case the Company shall take a record of the holders of its Common Stock for the purpose of entitling them (i) to receive
a dividend or other distribution payable in Common Stock, Options or Convertible Securities or (ii) to subscribe for or purchase
Common Stock, Options or Convertible Securities, then such record date shall be deemed to be the date of the issue or sale of the
shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution
or the date of the granting of such right of subscription or purchase, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Sections 3(a) and 3(b) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such
Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="text-underline-style: double">d) </FONT><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">e)
<U>Fundamental Transaction</U>. If, at any a) any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of
the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the
right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder, the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders
of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
&ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted or (so that from and after the occurrence or
consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally, may exercise every right and power of the Company prior thereto and the Successor
Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction
Documents with the same effect as if such Successor Entity or Successor Entities, jointly and severally, had been named as the Company
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">f) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><U>Black
Scholes Value</U>. Notwithstanding the foregoing and the provisions of Section 3(e) above, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of any Fundamental Transaction (or if later,
the date of the public announcement of the Fundamental Transaction), the Company or the Successor Entity (as the case may be) shall purchase
this Warrant from the Holder by paying to the Holder cash in an amount equal to the Black Scholes Value (as defined below). Payment of
such amounts shall be made by the Company (or at the Company&rsquo;s direction) to the Holder on or prior to the later of (A) the second
(2nd) Trading Day after the date of such request and (B) the date of consummation of such Fundamental Transaction; provided, however,
if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors
or the consideration is not in all stock of the Successor Entity, the Holder shall only be entitled to receive from the Company or any
Successor Entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same
proportion), at the Black Scholes Value (as defined below) of the unexercised portion of this Warrant, that is being offered and paid
to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">For purposes of this
Section 3(f), &ldquo;<U>Black Scholes Value</U>&rdquo; means the value
of the unexercised portion of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)
a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100%
and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the
Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price
per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period
beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or
the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&rsquo;s request pursuant
to this Section 3(f), (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated
Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">g) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">h) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1.5in; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1.5in; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company deliver to the Holder in accordance with Section 5(h) at least 20 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights
or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or
any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in
such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">i) <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market on which the Common Stock is then listed,
the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period
of time deemed appropriate by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions
of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder
or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company
within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant
in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its
agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined
in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall
be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">d) <U>Transfer
Restrictions</U>. As a condition of any transfer of this Warrant, the Holder or transferee of this Warrant, as the case may be,
shall comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall
the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="margin-left: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 1in; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">e) <U>
Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.5in; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BIOVIE
    INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 4%"></TD>
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">BIOVIE INC.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 1.5in">&nbsp;</TD>
  <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Warrant Shares shall be delivered to
the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 1.5in">&nbsp;</TD>
  <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(4) <U>Accredited Investor</U>.
The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __,
    ______</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _____________________________</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ______________________________</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>bivi-20220715_8ka1ex10z1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of July 15, 2022, between BioVie Inc., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its
successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined
below) and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally
and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.<BR>
DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Amended
Registration Rights Agreement</U>&rdquo; shall have the meaning ascribed to such term in Section 4.17.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <FONT STYLE="background-color: white"><U>provided</U>, <U>however</U>, for clarification,
commercial banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay at home,&rdquo; &ldquo;shelter-in-place,&rdquo;
&ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations
at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers)
of commercial banks in The City of New York are generally open for use by customers on such day</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) each Purchaser&rsquo;s obligation to pay the Subscription Amount and (ii)
the Company&rsquo;s obligation to deliver the Securities, in each case, have been satisfied or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the Class A common stock of the Company, par value $0.0001 per share, and any other class of securities
into which such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company that would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time)
and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time)
on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(jj).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(jj).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(bb).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Information
Statement</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lead
Purchaser</U>&rdquo; means Acuitas Group Holdings, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $1.65, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(jj).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Principal
Stockholder</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement covering the resale by the Purchasers of the Shares and Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock other than the Warrant Shares issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market
(or any successor entity) from the stockholders of the Company with respect to the transactions contemplated by the Transaction
Documents, including the issuance of all of the Shares and Warrant Shares in excess of 19.99% of the issued and outstanding Common
Stock on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Written Consent</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as
specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange, the Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means West Coast Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 721
N. Vulcan Ave., 1<SUP>st</SUP> FL, Encinitas, CA 92024 and an email address of cs@wcsti.com, and any successor transfer agent
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, the warrants to purchase shares of Common Stock delivered to the Purchaser at the Closing in accordance with Section 2.2(a),
in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
<B>PURCHASE AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of Six Million Dollars ($6,000,000) of Shares
and Warrants. At the Closing, each Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately
available funds equal to such Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such
Purchaser, and the Company shall deliver to each Purchaser its respective Shares and Warrants, as determined pursuant to Section
2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2. Upon satisfaction of the covenants
and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing
documentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis,
a certificate evidencing a number of Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase
Price, registered in the name of such Purchaser, or, at the election of such Purchaser, evidence of the issuance of such Purchaser&rsquo;s
Shares hereunder as held in DRS book-entry form by the Transfer Agent and registered in the name of such Purchaser, which evidence
shall be reasonably satisfactory to such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 200% of such
Purchaser&rsquo;s Shares, with an exercise price equal to $1.82, subject to adjustment as set forth therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a certificate of the Company executed by the Chief Executive Officer and Chief Financial Officer of the Company certifying that
the conditions specified in Section 2.3(b) have been fulfilled in a form reasonably acceptable to the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
the Amended Registration Rights Agreement duly executed by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
at least one (1) Business Day prior to the Closing Date, the Company shall have provided each Purchaser with the Company&rsquo;s
wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified in writing by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein
in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by
materiality, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent
representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Company shall have filed with the Nasdaq Capital Market a Notification Form: Listing of Additional Shares for the listing
of the Shares and Warrant Shares, and shall have received no objections to such form from the staff of The Nasdaq Stock Market,
LLC; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
the Stockholder Approval shall have been obtained and the definitive Information Statement shall have been mailed to the Company&rsquo;s
stockholders entitled thereto in accordance with Section 4.11(b) at least twenty (20) calendar days prior to the Closing Date
and the consummation of the transactions contemplated hereby shall be permitted by Regulation 14C of the Exchange Act (including
Rule 14c-2 promulgated under the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.<BR>
REPRESENTATIONS AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained
in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties
to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. The Company has no subsidiaries and any references to subsidiaries in the Transaction Documents shall be
disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company is an entity duly incorporated or otherwise organized, validly existing and
in good standing under the laws of the State of Nevada, with the requisite power and authority to own and use its properties and
assets and to carry on its business as currently conducted. The Company is not in violation nor default of any of the provisions
of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. The Company is
duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which
the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be
so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse
effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results
of operations, assets, business, stockholders&rsquo; equity, prospects or condition (financial or otherwise) of the Company, or
(iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has
been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and
authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s articles of incorporation, bylaws
or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of
the Company, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company
debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of the Company is
bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected;
except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority
or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other
than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission pursuant to this
Agreement, (iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities
and the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) the filing
of Form D with the Commission and such filings as are required to be made under applicable state securities laws and (v) the Stockholder
Approval (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company other than restrictions on transfer provided for in the Transaction Documents. The Warrant Shares, when issued in accordance
with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. The Company has reserved
from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the
Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)(i)</U>, which
<U>Schedule 3.1(g)(i) </U>shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates
of the Company as of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report
under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans,
the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the
Securities and as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or
exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments,
understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or Common
Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Purchasers). Except as set forth in the SEC Reports, there are no outstanding securities
or instruments of the Company with any provision that adjusts the exercise, conversion, exchange or reset price of such security
or instrument upon an issuance of securities by the Company. Except as set forth in the SEC Reports, there are no outstanding
securities or instruments of the Company that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company is or may become bound to redeem a security of the Company. The Company does
not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All
of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as
applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The
financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during
the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company as of and for the dates thereof and the results of operations and cash
flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any
liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant
to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company stock option plans or as disclosed in the SEC Reports.
The Company does not have pending before the Commission any request for confidential treatment of information. Except for the
issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
business, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company
under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at
least one (1) Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local
or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could,
if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under
federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company,
there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director
or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company, and the Company is not a party to
a collective bargaining agreement, and the Company believes that their relationships with its employees are good. To the knowledge
of the Company, no executive officer of the Company is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract
or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer
does not subject the Company to any liability with respect to any of the foregoing matters. The Company is in compliance with
all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions
of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. The Company: (i) is not in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice
of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement
or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation
has been waived), (ii) is not in violation of any judgment, decree, or order of any court, arbitrator or other governmental authority
or (iii) is not or has not been in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company (i) is in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) has received all permits licenses or other approvals required of it under applicable Environmental Laws to conduct its business;
and (iii) is in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii)
and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company possesses all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and the Company has not received any notice of proceedings relating to the revocation or modification of
any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company has good and marketable title in fee simple to all real property owned by them and good and
marketable title in all personal property owned by them that is material to the business of the Company, in each case free and
clear of all Liens, except for (i) Liens described in the SEC Reports, (ii) Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and (iii) Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP
and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by
the Company are held by them under valid, subsisting and enforceable leases with which the Company is in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company has, or has rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar
rights necessary or required for use in connection with its business as described in the SEC Reports and which the failure to
so have could have or reasonably be expected to have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property
Rights</U>&rdquo;). None of, and the Company has not received a notice (written or otherwise) that any of, the Intellectual Property
Rights have expired, terminated or been abandoned, or are expected to expire or terminate or be abandoned, within two (2) years
from the date of this Agreement. The Company has not received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate
or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect.
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by
another Person of any of the Intellectual Property Rights. The Company has taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company is insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the business in which the Company is engaged, including, but not limited to, directors
and officers insurance coverage at least equal to the aggregate Subscription Amount. The Company has no reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions with Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of
the Company and, to the knowledge of the Company, none of the employees of the Company, is presently a party to any transaction
with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for
the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest
or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii)
other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company is in compliance with any and all applicable requirements of
the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company maintains
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only
in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company
has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the
reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure
controls and procedures of the Company as of the end of the period covered by the most recently filed periodic report under the
Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic
report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and
procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the
internal control over financial reporting (as such term is defined in the Exchange Act) of the Company that have materially affected,
or is reasonably likely to materially affect, the internal control over financial reporting of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. No brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with
respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection
with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers
as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the
Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo;
subject to registration under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Registration Rights</U>. Except as set forth in the SEC Reports and other than each of the Purchasers, no Person has any right
to cause the Company to effect the registration under the Securities Act of any securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the
listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the
foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company
is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection
with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company&rsquo;s articles of incorporation (or similar charter
documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or
their agents or counsel with any information that it believes constitutes or might constitute material, non-public information.
The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in
securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company,
its business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, when taken together
as a whole, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole
do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the
transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would
require the registration of any such securities under the Securities Act, or (ii) any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. The SEC Reports set forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company,
or for which the Company has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any
liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether
or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance
with GAAP. The Company is not in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company (i) has made or filed all United States federal, state and local income and all foreign
income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any
such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of
the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only
to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Foreign Corrupt Practices</U>. Neither the Company nor, to the knowledge of the Company, any agent or other person acting on
behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other
unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose
fully any contribution made by the Company, (or made by any person acting on its behalf of which the Company is aware) which is
in violation of law or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth on <U>Schedule 3.1(ff)</U> of the Disclosure Schedules. To
the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange
Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report
on Form 10-K for the fiscal year ending June 30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction
Documents and the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities.
The Company further represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company
and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<FONT STYLE="text-underline-style: double"><U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>.</FONT> Anything
in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.13), it is understood
and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser
agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities
based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or
other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s
publicly-traded securities, (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such
Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock and (iv) each
Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Securities are outstanding, including, without limitation, during the periods that
the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if
any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the
hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has,
(i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another
to purchase any other securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is
manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, licensure, application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance
would not have or would not reasonably be expected to have a Material Adverse Effect. There is no pending, completed or, to the
Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company, and the Company has not received any notice, warning letter or other
communication from the FDA or any other governmental entity, which (i) contests the development, licensure, registration, or approval
of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion
of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or
orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company, (iv) enjoins production at any facility of the Company, (v) enters or proposes
to enter into a consent decree of permanent injunction with the Company, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company, and which, either individually or in the aggregate, would have or would reasonably be expected
to have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in
all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed
by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed,
produced or marketed by the Company nor has the FDA expressed any concern as to approving for marketing any product being developed
or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)
in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair
market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock
option granted under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there
is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
the grant of stock options with, the release or other public announcement of material information regarding the Company or its
financial results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers,
employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company has not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data, except in
each case as would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect; (ii)
the Company is presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of
any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the
privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse
Effect; (iii) the Company has implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)
the Company has implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Office of Foreign Assets Control</U>. Neither the Company nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control
of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Affiliates owns or controls, directly or indirectly, five percent (5%)
or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Affiliates
exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation
by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Money Laundering</U>. The operations of the Company are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>No Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under
the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other
officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;
and, together, &ldquo;<U>Issuer Covered Persons</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for
a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any
Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure
obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Other Covered Persons.</u> The Company is not aware of any person (other than any Issuer
Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with
the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>Notice of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i)
any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become
a Disqualification Event relating to any Issuer Covered Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Own
Account</U>. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons
to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration
Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction
Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its
financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment;
and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such
Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates,
such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such
Purchaser&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance
of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating
or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.<BR>
OTHER AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;<U>Transfer
Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities,
other than transfers pursuant to an effective registration statement, Rule 144, to the Company, to an Affiliate of a Purchaser
or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to
the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration
of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing
to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following
form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a)
UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a
registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such
Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be
subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required
in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the
Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request
in connection with a pledge or transfer of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;Certificates
evidencing the Shares and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof),
(i) while a registration statement (including the Registration Statement) covering the resale of such security is effective under
the Securities Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144 (assuming cashless exercise
of the Warrants), (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the
Warrants), without the requirement for the Company to be in compliance with the current public information required under Rule
144 as to such Shares and Warrant Shares and without volume or manner-of-sale restrictions, or (iv) if such legend is not required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser if required
by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any
portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Warrant
Shares, or if such Shares or Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current
public information required under Rule 144 (assuming cashless exercise of the Warrants), or if the Shares or Warrant Shares may
be sold under Rule 144 without the requirement for the Company to be in compliance with the current public information required
under Rule 144 as to such Shares or Warrant Shares or if such legend is not otherwise required under applicable requirements of
the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant
Shares shall be issued free of all legends. The Company agrees that at such time as such legend is no longer required under this
Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of
a certificate representing Shares or Warrant Shares, as the case may be, issued with a restrictive legend (such date, the &ldquo;<U>Legend
Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free
from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer
Agent that enlarge the restrictions on transfer set forth in this Section 4.1. Certificates for Securities subject to legend removal
hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime
broker with the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with
respect to the Common Stock as in effect on the date of delivery of a certificate representing Shares or Warrant Shares, as the
case may be, issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements,
or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance
with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates
representing Securities as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;<U>Furnishing
of Information</U>. Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the
Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements
of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of
the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release or
file a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered
to any of the Purchasers by the Company or any of its officers, directors, employees, Affiliates or agents in connection with
the transactions contemplated by the Transaction Documents. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall
consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither
the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior
consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure
is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public
statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the
prior written consent of such Purchaser, except (a) as required by federal securities law in connection with (i) any registration
statement contemplated by this Agreement and (ii) the filing of final Transaction Documents with the Commission and (b) to the
extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such
disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that
any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of
receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in
writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company
understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7&nbsp;<U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion
of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior
practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding
litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of
a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such
Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants
or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against
the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is
not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially
determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser
Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company
in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the
extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed
after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable
opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser
Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.
The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected
without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of
the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of
the Common Stock on the Trading Market on which it is currently listed, and shall apply to list or quote all of the Shares and
Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading
Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause
all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company
will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and
will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the
Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository
Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository
Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11&nbsp;<U>Stockholder
Approval</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;Immediately
following the execution and delivery of this Agreement and in lieu of calling a meeting of the Company&rsquo;s stockholders, the
Company shall (i) submit the Stockholder Written Consent, in the form attached hereto as <U>Exhibit A</U> (the &ldquo;<U>Stockholder
Written Consent</U>&rdquo;), to Acuitas Group Holdings, LLC (the &ldquo;<U>Principal Stockholder</U>&rdquo;) and (ii) use its
reasonable best efforts to obtain the Stockholder Written Consent, duly executed by the Principal Stockholder and duly delivered
to the Company in accordance with the Nevada Revised Statutes, from the Principal Stockholder before 9:00 a.m. New York time,
on the day immediately following the date of this Agreement. The parties hereto agree and acknowledge that the Stockholder Written
Consent shall be void and of no further effect if this Agreement is terminated in accordance with the terms and conditions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;Within
five (5) Business Days after the date of this Agreement, the Company shall file with the Commission a preliminary information
statement in accordance with Regulation 14C promulgated under of the Exchange Act (such preliminary information statement and
any revised or definitive information statement, the &ldquo;<U>Information Statement</U>&rdquo;) relating to the Stockholder Approval.
Each Purchaser shall reasonably cooperate with the Company in the preparation of the preliminary Information Statement, the definitive
Information Statement and any amendments or supplements thereto and shall promptly furnish to the Company the information relating
to such Purchaser required by the Exchange Act for inclusion therein. Prior to filing with the Commission, the Company shall provide
each Purchaser and its counsel a reasonable opportunity to review and comment on the Information Statement and shall consider
in good faith for inclusion in the Information Statement any comments made such Purchaser or its counsel that are provided in
a timely manner. The Company shall use reasonable best efforts to respond as promptly as practicable to any comments of the Commission
with respect to the Information Statement and to cause the Information Statement in definitive form to be mailed to the holders
of shares of the Common Stock entitled thereto as promptly as reasonably practicable after (i) the tenth (10th) calendar day after
the initial filing of the preliminary Information Statement with the Commission if by such date the Commission has not informed
the Company that it intends to review the Information Statement or (ii) if the Commission has, by the tenth (10th) calendar day
after the filing of the initial preliminary Information Statement with the Commission, informed the Company that it intends to
review the Information Statement, the date on which the Commission confirms that it has no further comments on the Information
Statement. The Company shall notify each Purchaser promptly of (and in any event no more than one (1) Business Day after) the
receipt of any comments from the Commission or its staff and of any request by the Commission or its staff for any amendments
or supplements to the preliminary Information Statement or the definitive Information Statement, and if required, the Company
shall mail to the holders of shares of Common Stock entitled thereto, as promptly as reasonably practicable, such amendment or
supplement. Prior to filing with the Commission, the Company shall provide each Purchaser and its counsel a reasonable opportunity
to review and comment on any such amendments or supplements to the Information Statement and shall reasonably consider in good
faith for inclusion in any amendments or supplements any comments made by such Purchaser or its counsel that are provided in a
timely manner. If at any time prior to the Closing any event shall occur, or fact or information shall be discovered, that should
be set forth in an amendment or supplement to the Information Statement so that such document would not include any misstatement
of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances
under which they are made, not misleading, the party that discovers such information shall as promptly as practicable notify the
other parties hereto and the Company shall prepare and file with the Commission such amendment or supplement, in consultation
with and subject to review by each Purchaser and its counsel as promptly as practicable and, to the extent required by law, cause
such amendment or supplement to be disseminated to the holders of shares of Common Stock entitled thereto. Notwithstanding the
foregoing, in the event that this Agreement is terminated in accordance with the terms and conditions hereof, the Company shall
not be required, after the date of termination, to prepare, file and mail the Information Statement pursuant to this Section 4.11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to
treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time
as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release
as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and
the information included in the Disclosure Schedules (other than as disclosed to its legal and other representatives). Notwithstanding
the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and
agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions
in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4 and (ii) no Purchaser shall be restricted or prohibited from
effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate
portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge
of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant
set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment
decision to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14&nbsp;<U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers
at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15&nbsp;<U>Acknowledgment
of Dilution</U>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares
of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its
obligations under the Transaction Documents, including, without limitation, its obligation to issue the Shares and Warrant Shares
pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay
or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless
of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16&nbsp;<U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the
Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be
required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares
in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17&nbsp;<U>Amended
Registration Rights Agreement</U>. Concurrently with the Closing, the Company and the Lead Purchaser shall amend and restate that
certain Registration Rights Agreement, dated as of June 10, 2021, by and between the Company and the Lead Purchaser (the &ldquo;<U>Existing
Registration Rights Agreement</U>&rdquo;), to amend the definition of &ldquo;Registrable Securities&rdquo; in the Existing Registration
Rights Agreement to include the Shares and the Warrant Shares as Registrable Securities thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
<B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;<U>Termination</U>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before August 15, 2022; <U>provided</U>, <U>however</U>, that no such termination will affect the
right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay the reasonable legal
fees and expenses of counsel to the Lead Purchaser in connection with the transactions contemplated by the Transaction Documents,
up to a maximum amount of $25,000.00, which amount shall be paid directly by the Company at the Closing or upon termination of
this Agreement so long as such termination did not occur as a result of a material breach by such Purchaser of any of its obligations
hereunder (as the case may be). In the event that the Company receives any written comments from the Commission with respect to
the Information Statement, the Company shall reimburse the Lead Purchaser for the reasonable fees and expenses of counsel to the
Lead Purchaser in connection with responding to such comments, up to a maximum amount of $75,000.00, which amount shall be paid
directly by the Company within thirty (30) days of receipt of the Lead Purchaser&rsquo;s written request for reimbursement. The
Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction
letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied
in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, with no rejection notice received, (b) the next Trading Day after
the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any
Trading Day, with no rejection notice received, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed
by the Company and Purchasers. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair
the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8&nbsp;<U>No
Third-Party Beneficiaries</U>. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to
the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action
or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence
an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company
under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an
original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in
the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common
Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price
paid to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such
Purchaser&rsquo;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances
shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with
the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do
so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Biovie
                                         inc.</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
                                            for Notice</U>:</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
        West Nye Lane Suite 201</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carson
        City, NV 89703</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Cuong Do </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong
    Do</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of
Purchaser:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acuitas Group Holdings, LLC	</FONT></TD>
</TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized
Signatory of Purchaser</I>:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Terren S. Peizer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
                                                                                                                                                                                                                   <TD STYLE="text-align: justify; width: 54%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Terren S. Peizer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized
Signatory:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address of Purchaser:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice to
Purchaser:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2120 Colorado Avenue, #230</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Santa Monica, California 90404</P></TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap">&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap">&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD>
<TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="4" STYLE="white-space: nowrap">Address for Delivery of Securities to Purchaser (if not same as address for notice):</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Amount: </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">$</TD>
    <TD STYLE="text-indent: 10pt; vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000,000.60</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 10pt; vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,363,364</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 10pt; vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,272,728</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>bivi-20220715.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9qJZs7xRiXgOn8uMb3VcSaeA6aP9zJFx2ZkhtmRyffnaHyYuytHZtCy6a8hGwQ8N -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:bivi="http://nanoantibiotics.com/20220715" elementFormDefault="qualified" targetNamespace="http://nanoantibiotics.com/20220715">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nanoantibiotics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20220715_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20220715_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bivi-20220715_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bivi-20220715_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Cover" xlink:href="bivi-20220715.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140348681903824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">BioVie
Inc., a Nevada corporation (the &#8220;Company&#8221;), is filing this Amendment No. 1 on Form 8-K/A (this &#8220;Amendment&#8221;) to
amend the Current Report on Form 8-K, originally filed by the Company with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on July 15, 2022 (the &#8220;Original Report&#8221;), solely to delete references to the placement agent that were inadvertently included
in the Original Report and Exhibit 10.1 due to an administrative error. The full text of the Original Report is repeated in this Amendment
for convenience, but has not been modified from the text of the Original Report except as described above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 15,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioVie Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2510769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680 W Nye Lane Suite 201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carson City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-3162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIVI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>bivi-20220715_8ka1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bivi-20220715.xsd" xlink:type="simple"/>
    <context id="From2022-07-15to2022-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-07-15to2022-07-15">0001580149</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-07-15to2022-07-15">true</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-07-15to2022-07-15">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-07-15to2022-07-15">2022-07-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-07-15to2022-07-15">BioVie Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-07-15to2022-07-15">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-07-15to2022-07-15">001-39015</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-07-15to2022-07-15">46-2510769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-07-15to2022-07-15">680 W Nye Lane Suite 201</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-07-15to2022-07-15">Carson City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-07-15to2022-07-15">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-15to2022-07-15">89703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-07-15to2022-07-15">775</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-07-15to2022-07-15">888-3162</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-07-15to2022-07-15">Class A Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-07-15to2022-07-15">BIVI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-07-15to2022-07-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2022-07-15to2022-07-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-07-15to2022-07-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-07-15to2022-07-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-07-15to2022-07-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-07-15to2022-07-15">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="From2022-07-15to2022-07-15">BioVie
Inc., a Nevada corporation (the &#x201c;Company&#x201d;), is filing this Amendment No. 1 on Form 8-K/A (this &#x201c;Amendment&#x201d;) to
amend the Current Report on Form 8-K, originally filed by the Company with the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
on July 15, 2022 (the &#x201c;Original Report&#x201d;), solely to delete references to the placement agent that were inadvertently included
in the Original Report and Exhibit 10.1 due to an administrative error. The full text of the Original Report is repeated in this Amendment
for convenience, but has not been modified from the text of the Original Report except as described above.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " !.B?)4EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( $Z)\E2JQ"(6,P$
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M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " !.B?)4)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 3HGR5&60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" !.B?)4!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( $Z)\E0RD6IO[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $Z)\E297)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 3HGR5 R.'S*D!0  I1,  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $Z)\E2?H!OP
ML0(  .(,   -              "  ><-  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 3HGR5)>*NQS     $P(   L              ( !PQ   %]R96QS
M+RYR96QS4$L! A0#%     @ 3HGR5*K$(A8S 0  (@(   \
M ( !K!$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $Z)\E0D'INBK0
M /@!   :              "  0P3  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( $Z)\E1ED'F2&0$  ,\#   3              "
M ?$3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  #L5
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="bivi-20220715_8ka1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" original="bivi-20220715_8ka1.htm">bivi-20220715_8ka1.htm</File>
    <File>bivi-20220715.xsd</File>
    <File>bivi-20220715_8ka1ex10z1.htm</File>
    <File>bivi-20220715_8ka1ex4z1.htm</File>
    <File>bivi-20220715_lab.xml</File>
    <File>bivi-20220715_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bivi-20220715_8ka1.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "bivi-20220715_8ka1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bivi-20220715_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bivi-20220715_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bivi-20220715.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "bivi",
   "nsuri": "http://nanoantibiotics.com/20220715",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bivi-20220715_8ka1.htm",
      "contextRef": "From2022-07-15to2022-07-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://nanoantibiotics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bivi-20220715_8ka1.htm",
      "contextRef": "From2022-07-15to2022-07-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001520138-22-000313-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-22-000313-xbrl.zip
M4$L#!!0    ( $Z)\E0? P66+0,  , +   1    8FEV:2TR,#(R,#<Q-2YX
M<V2U5=MRVC 0?6YG^@^JW^4+-!<()),ADY0,N12:3)J7CK!ET$1(CB1SZ==7
MDFWN4*"MGZ3=<\[N2KMR[6(\H&"(A22<U9W ]1V 6<@CPGIUYZD#+SN-9M,!
M%^>?/@+]U3Y#"*X)IE$57/$0-EG,S\ ]&N JN,$,"Z2X. //B*;&PJ\)Q0(T
M^""A6&'MR")5P9$;?$$ PAUTGS&+N'AJ-Z>Z?:426?6\T6CD,CY$(R[>I!OR
MP6Z"'854*J=J_MC/O]WH=T2&4W+E_?95GHS;Y*7WP$[3NV[Y.>P@?'F,'BN_
M;J_'I=>WOAJT)W',T-?)CW2BOKZJQN08G?9O1M].[[.0-1GV\0 !?1E,UAU3
M7U[>J.QRT?-*OA]X+W>MCL4Y&; ZIH2]K8,'E4K%L]X"NH(<=P4MI,N><7>1
MQ%-E[25;\(1)A5BX@(_4E# //O(RYP*4K(4>9U!20".\A),X='M\Z&F'QI=*
M!3"5L(=0,@7'2':M:.Y8 $NA5H':N R":I)@N1::N18(73*<)<L0XX@ITB5<
MD="VI@7[)\&1'C"*!YBI:RX&5SA&*=7YO*>(DIC@R $*B1Y6IM=D@D*\FVC1
MMX@QKMM;SUAN,;8D(;I_M>%#S5QT57"*O^L*@%GHP=H:PF"\!M=OA -(5'>R
MI1'3TE8NPC%AQ,;,!RD T(Q-:LK42TNI><O@.8E4XNB!G=MU(K#4/%M$2QMR
M8@[90 H1#5.Z'V>6REI*;B@.:W9\Q;"T<0SLD%5-.]0=2<PSY^2VOL!QW3%M
M 8M;^JE+<W6[%! CO67([,DOGT8>N)! (EQ167D$M A/L%!$]^S<I&>I$V7H
MCW-A@(DC'>#]BY(IZNY;LJ9@^A]K;1G]^2+S.?%F@Y+OEX>IILOE0@&V,IS;
MGLCL<6_QT$IMH9@=+'C0F&!0@N7 '<MHEND^2<Q.8+\D"MX!26QXJ-?%EYO@
M9F%;:->@&Q[\K4'7<CQ,E2PL!Z<P_WOXBQRLS%Y)+%QGI(1G)(RH#_T EH+-
MZ?R):??RH"8(><J4F.S3"/.48G/8;<Q^[+M=1('/+L'\ZP\->T 7K 9?UP(U
M+U/3R]]02P,$%     @ 3HGR5&<Q[LMB%P  /G0  !8   !B:79I+3(P,C(P
M-S$U7SAK83$N:'1M[5UI<]LXTO[N*O\'K'9FRZY7%W78\A%MR;+L*'9DQY)S
MS!<72$(28XID>.C(KW^[ 9X2*5^R-YF:V=EQ3 *-[D8?#QH <_S?^40G4V8[
MFFF\RTG%<HXP0S%5S1B]RWGNL-#(_;>YO74\=J$=M#6<=[FQZUJ'I=)L-BO.
MJD73'I6D@X.#TAS;Y$2CPWEJNTJY+)6^?KSL*V,VH07-<%QJ*"SLI&O&?39]
M?!LVE6U=2S3%)\$@U=(*:7BK1AWBC?=*XF6BJ9O:M"Z:ND%3S3%K%6E_'1^B
M1=AAGM560IY!0O;UY.8R:NZFMX^:EER;&L[0M"?4A3E$2O5"N5*H[,6(%!RF
M) C![\61.7V03J-0E0(Z*Y.3E!1?R]0)-:ZR)74'8\(+Z%&I! UM-LPDNU>"
MMT%#SRF,*+7"QD/JR+RA_R)!%9[9ILZ<U-;\3:*Y8GJ&:R_2.?9?)CHXMKM*
M&AXF&LG:-%*"00V3&JXF:Z:K*4Y1,2>\<7E?JN>XCS&JPD^"_QR[FJNSYG%)
M_(2W$^92@J0*[(>G3=_EVJ;A,L,M#!86*%T1O[W+N6SNEH0KEK!?R2=[_*]"
M@9QI3%</29^Y1Z1')^R0S-7Y$>F>\C_<E2LG=[?]/RNGYZW6-?Q ]DBA\-C>
MU=H=2GR7(NE=(.D3R-4:8:_G=*^?WC&P-1 #_NT .^ZB#1JRJ=XU5#:_8(N[
M,L2C>J,LU0Z>0K<>H]N:,$.%_[MG.AW=N;;'GD!I#[5]>B?=^5%"D(1'3Z%1
MN>N/J<V<N\H=#XJ"B,.?/87.*?)R[=.JKK"425PVU07^5+4I<=R%SM[E5,VQ
M=+HX)(9I,&[:VOP0S9#9:-_\-TU5F<&M'7^%ACUOPFQ-$88\=V\P*IS9Y@1G
MOE#>+TAUUXS^G",&" %#,>TP=6YSS6ARCTN)(38S:F+F<TV<^M1Q2@EI<5@(
M:<R&+,L<T0(CYZ'#4R*,3WB>.QSSL(CN5 ALOSAWU)S_V@6G?Y=SM(FE,^'H
M_E!)XF(XQ_3L8#1HQF?RT)>8:.I:B8. %'1C7-GAT_"YIN*;H<9LPD5AJ?FF
MW;U(3LQRYVBX4NIX_F@6Z-=45[F I&^[I]1ES4B$@%+T;J4;S&1&I^#-,EL)
M!H*'ODJ3>O8,32@9G&A%FQ-&'<]F3=_;#J%-0"QXE1P"J670%ZZ;.82O!-[H
MV6-$(6)E'/!_F,95W6)?[A#4->W8ZZ?K8)G'-*JQ04^984XTXZ%A'];+\KAI
MA(/W"2VL*-3WT)@_BO 0A,;C$O2'G_B_>-2^\716N*8CGESBD79"[9%F%%S3
M.B1E"T*[_T V7=><^,]FFNJ.#XE4+O^92_2631O&%;U/=*K<DZKE$L?4-?6(
M^"\#2N*]5*Q'+89@[@5'^PFY1++<7/,__Y;VRD="!O^_,1E*"2&XA%; "%)"
M!H'V0)M :NFQ&;DQ)]3(BP=Y2%RV-@SD \&BX:SF"TD=$?3: M6U$?RJ0,1A
M-BC*L:@1IQJ(6D%9C^7F;:\[Z)R2_J UZ/2/99M'X7ZG?7O3'70[?=+JG9+.
MU_;[5N^\0]I7'S]V^_WN5>^X)(-VD#@2"?I]:?7?=WOG@ZM>GIP6VT52*=<Q
M/F);2VC+I;+.@#U=A\X*7Z#!:@U_MZBJ!K\_60TQZP@G73%UG5H.2!O\2;C[
ML1M8_+&K!D/Y!&KU/Z,Y<=75=DL&):\:5,C* Y0R1H3_V*MLKJ7D:RYD*F''
M\0[IXY3XG*397^7E]B<WSZYN/A)AAQA\$:<=E"L<?18*IZ;B(?Q ^'^GA$ Y
M@LP_A^?G]J1\W2WW:D#NI7@G/EZNV2A<E%K+>"<T:V'3F1Y41BWOA "*],PB
MD7:#WO_8_-O:?+FX7]^4V6\@[,I-B* WG=Z W'2NKVX&Y/KVIG_;Z@T"LQI<
M$8BR PBE1*J2JQLBU7?477)U%C9XWR&Q.!S&X%9[ *V(=%"M)8QL\T+$4].K
M#("8E)A#<L,LTW;)3O [HX WF.,2-D7'LOEK!MK!5+,42.I+@>2:0]J. +SI
M$67_Z\VM*WD7IP?[SXXHHL3T+J?-W4,51II O[%*%PO@G1EI$2?!6*[YP=,7
MVUM2/4^0;%8,^LTG.#-V-GSTD6C *:A,,6U>O#LD'JR";2SMY5:FO>Q/NU@U
MW["1YF#IS\6B0/JL&TY__Y*UN[WO&T@C:</FFB>:^5ECI&LHQ<P)C<UKB)X>
MK80@)454=CISJKB\%B(\*>"(4(?T+:;@>E0EFD&ZKD/:L#Z B=E].YMZI=3G
M+Q!T-H0.U'/-QV;#L*NMC<9^WS!#!GQ,F>UJ"M4#V6!ID7M65AQK+BN@X RK
M2#.;6B&?U=J?F:ECV=@;"6,'\S)MR[>/O@O1I"TJNVU3S;#]$^/LYR78]\>&
MNHF(AX5X+$2XS++-*7I%,N0]@L]<L\>F5*5K ]\SL<@ZK5<>K_5J0NMGFLZ
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MOH6!W5JF4&/@1;ZHJUK-"Q\)32&6"6<0<(0&^&.8/W[7G:=S!1 DQ2T]?_.
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MA^%]>"D\'<637:&CV,O:IY(U4C!;5%3- 4B0K0#!HUJ$]'45-W!FMP;^1;R
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MCX"7Q;H%62L69JAUH1!4]N!BVUAAJ6Z=ZI,(EY.MS*WH-3_2VG?5N32%Y3S
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MYX J7"=5-X7&#PTH(S6S9HI1 !1//T==6+'FK44* T$H64V,+ZPT%O!J,!!
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MS PW&=+/TH]7U%7=?QCYELK8SH#;# ;])\-^EZ0JL-A@X597+4-G]&105NB
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M(Z^&D.*9M'?H]]/E%1Z=9="Y=U [69OMQA<Z],<6:#V<;S54*['M%MZ<&$(
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M743<'%SQV-<HRHEQIRU;15:X#X\PS@>/AW]<3NT/3OZ <8+/8;-_-BF:;Y!
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MH=,&'R#(QC$-#;3H';IQT 12PH_K"@>7&BI[F_N!5V9AT80R[ !K!%<%?Y^
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M+PQ&^K@U3ZG[1"RKI%W$T66%W;(+<PD:B9S.DDMJEFT>K;):GCWE:G0O^RY
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M3*N@V;)J7/5?96*I!!(%[!/?ZUQ&^_R#FZ;2(%K/R5!",S;N3H:QW6.<-B8
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M[%6/^5A=N?PNU84157>;W/UFR5V=S*TF>_]8A]4,M!V&]U2NV'3TAIA'X^A
M!UQ\Z#(IXY?%-(1C/,VN\W!ZW\$U9-VQY7Q>7$ UY&'S#$MBW_[PW!S]OL_A
MZ0Z!EJ((/F+A\Z=LC,IAG>#H:/^__) #NN=?D_%L7^VK?;6O]M6^VE?[:E_M
MJWVUK_;5OMI7^VI?[:M]K<SK<45Z%\58'U<L]UM U;]YQ/WGPW>V;!GR-%V5
MQ>ES%F?N4<-"-?/SC<H3('T0@\15T-\*3F,S5OF?]>1M/F=W^^XHV:]<C2Z'
M]*?<TCY"Z>D?P ,O!L$^L=<MQW+OM8_K7I5-BM.":G,*[-[TG+>B;[4-M8;
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M>!YIG]G6/9LECJ>J;+-%7+7;:> =7X,CY?'&D6(Y4AYO'"E_24=*NR>@P16
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M8WRYO@8G!U,%)*WIZX<LQFW/7OW$FKS37'S+Q;?2+8E4DQJ,;FVIC,B)0LR
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M\U+S)(JH(V25 F4CY[IZ<?O<C<.4:(^=E3Z5L!<X$L<EE17A?,KZ$=YM[9]
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M XX&L2?4%!TX#2NYS,&D"AV.$UKW/VRXFG2>J#9:M=24UVM&M(.J?EGU(CY
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M"8"I2MB64C2GWE2U\D8_BO3R=OK5F[)M4["JNR3<Y,F(G1?Q.V*X] %N3#Y
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M''%D7(F;T&QHZ&I",4_/WCTD8[Z6K %:W04:E+*-M/D8:7,@?;Z)\7#1KMP
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MJO3JLWW24D55RA'!924D4MT5!<Y$H@#3*64ND B0*'-).0R$<N#7:Q$H6ZI
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MV .J9Z)*7^*<-=W0Q&L)A%7))E[C-M]A&+2O.<_LDY+%7@\$YYP[W'-L@NJ
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MM]46W[A?[HVL]LC_4$L! A0#%     @ 3HGR5!\#!98M P  P L  !$
M         ( !     &)I=FDM,C R,C W,34N>'-D4$L! A0#%     @ 3HGR
M5&<Q[LMB%P  /G0  !8              ( !7 ,  &)I=FDM,C R,C W,35?
M.&MA,2YH=&U02P$"% ,4    " !.B?)488&($M6=   9 00 '
M    @ 'R&@  8FEV:2TR,#(R,#<Q-5\X:V$Q97@Q,'HQ+FAT;5!+ 0(4 Q0
M   ( $Z)\E1I*GOJ5TH  *:O 0 ;              "  0&Y  !B:79I+3(P
M,C(P-S$U7SAK83%E>#1Z,2YH=&U02P$"% ,4    " !.B?)4<I3DWOX*  "
MA@  %0              @ &1 P$ 8FEV:2TR,#(R,#<Q-5]L86(N>&UL4$L!
M A0#%     @ 3HGR5++?0YY:!P  XU<  !4              ( !P@X! &)I
I=FDM,C R,C W,35?<')E+GAM;%!+!08     !@ & )P!  !/%@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
